Risk factors for recurrence of abdominal aggressive fibromatosis after radical surgery: An 8-year observational study from a chinese high-volume sarcoma center
Background: There are lacking standard treatment guidelines for aggressive fibromatosis (AF) because of its rarity.
Aim: This study aimed to investigate the risk factors for recurrence and survival of abdominal AF after radical surgical resection.
Methods: From August 2012 to December 2020, a retrospective analysis was conducted on the clinical data of 69 aggressive fibromatosis in Shanghai Public Health Clinical Center Affiliated to Fudan University, with the tumor locating either in the abdominal wall or in the abdominal cavity. The main observation endpoint were progression-free survival time (PFS) and overall survival time (OS).
Results: All 69 patients achieved microscopic R0 resection, 10 (14.5%) had local recurrence, and 3 (4.3%) died. The progression-free survival rate (PFS) after 1, 3, 5 and 10 years was 96.8%, 87.7%, 78.8% and 78.8%, respectively. The overall survival rate (OS) after 1, 3, 5 and 10 years was 100%, 100%, 92.9%, and 81.3%, respectively. In 10 patients with recurrence, the median recurrence time was 17.6 months. Concomitant familial adenomatous polyposis (FAP) and history of previous recurrence were independent risk factors of postoperative recurrence.
Conclusion: After radical surgery of abdominal AF, the local recurrence rate was 15%. Concomitant FAP and a previous history of recurrence were independent risk factors of postoperative recurrence. R0 and a combined organ resection should be performed especially in FAP patients to minimize the recurrence and improve the prognosis.
Relevance for patients: The current study identifies the risk factors of recurrence in AF and suggests R0 resection especially in concomitant FAP patients. A wait-and-see strategy should not be generally implemented
[1] Ganeshan D, Amini B, Nikolaidis P, Assing M, Vikram R. Current Update on Desmoid Fibromatosis. J Comput Assist Tomogr 2019;43:29-38.
[2] Ratan R, Roland CL, Bishop AJ. Desmoid Fibromatosis: Management in an Era of Increasing Options. Curr Oncol Rep 2021;23:41.
[3] Villalobos VM, Hall F, Jimeno A, Gore L, Kern K, Cesari R, et al. Long-term Follow-up of Desmoid Fibromatosis Treated with PF-03084014, an Oral Gamma Secretase Inhibitor. Ann Surg Oncol 2018;25:768-75.
[4] van Houdt WJ, Husson O, Patel A, Jones RL, Smith MJ, Miah AB, et al. Outcome of Primary Desmoid Tumors at all Anatomic Locations Initially Managed with Active Surveillance. Ann Surg Oncol 2019;26:4699-706.
[5] Bonvalot S, Eldweny H, Haddad V, Rimareix F, Missenard G, Oberlin O, et al. Extra-abdominal Primary Fibromatosis: Aggressive Management could be Avoided in a Subgroup of Patients. Eur J Surg Oncol 2008;34:462-8.
[6] Improta L, Tzanis D, Bouhadiba T, Abdelhafidh K, Bonvalot S. Desmoid Tumours in the Surveillance Era: What are the Remaining Indications for Surgery? Eur J Surg Oncol 2020;46:1310-4.
[7] Seinen JM, Niebling MG, Bastiaannet E, Pras B, Hoekstra HJ. Four Different Treatment Strategies in Aggressive Fibromatosis: A Systematic Review. Clin Transl Radiat Oncol 2018;12:1-7.
[8] Desmoid Tumor Working Group. The Management of Desmoid Tumours: A Joint Global Consensus-based Guideline Approach for Adult and Paediatric Patients. Eur J Cancer 2020;127:96-107.
[9] Harati K, Jaenisch A, Behr B, Goertz O, Harati A, Hirsch T, et al. Effect of Surgical Margins on Prognosis in Aggressive Fibromatosis: A Single-institutional Analysis of 90 patients. Oncol Lett 2017;14:5129-34.
[10] Zhou SC, Pei W, Sun Z, Zhou ZX, Wang S, Liang JW, et al. Clinicopathological Characteristics and Prognostic Factors for the Recurrence of Abdominal Desmoid Tumors: A Retrospective Study of 113 Patients from Two Chinese Hospitals. Chin Med J (Engl) 2020;134:1505-7.
[11] Janssen ML, van Broekhoven DL, Cates JM, Bramer WM, Nuyttens JJ, Gronchi A, et al. Meta-analysis of the Influence of Surgical Margin and Adjuvant Radiotherapy on Local Recurrence After Resection of Sporadic Desmoidtype Fibromatosis. Br J Surg 2017;104:347-57.
[12] Santti K, Beule A, Tuomikoski L, Rönty M, JääskeläinenAS, Saarilahti K, et al. Radiotherapy in Desmoid Tumors: Treatment Response, Local Control, and Analysis of Local Failures. Strahlenther Onkol 2017;193:269-75.
[13] Jelinek JA, Stelzer KJ, Conrad E, Bruckner J, Kliot M, KohW, et al. The Efficacy of Radiotherapy as Postoperative Treatment for Desmoid Tumors. Int J Radiat Oncol Biol Phys 2001;50:121-5.
[14] Cho JY, Gupta S, Cho HS, Park MS, Mok SJ, Han I, et al. Role of Nonsteroidal Anti-inflammatory Drug in Treatment of Extra-abdominal Desmoid Tumors. Clin Orthop Surg 2018;10:225-33.
[15] Shimizu K, Hamada S, Sakai T, Koike H, Yoshida M, Nishida Y. Efficacy of Low-dose Chemotherapy with Methotrexate and Vinblastine for Patients with Extraabdominal Desmoid-type Fibromatosis: A Systematic Review. Jpn J Clin Oncol 2020;50:419-24.